Vivian Trang

Company: Pfizer

Job title: Principal Scientist

Seminars:

SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6 & Shows Clinical Efficacy in Multiple Solid Tumor Indications 9:00 am

Explore how SGN-B6A is an investigational, first-in-class ADC, which shows high specificity towards integrin beta-6 Overview of SGN-B6A preclinical and clinical safety and efficacy data Discuss the rationale for clinical combination between SGN-B6A and CPIs Read more

day: Day Two